Showing 1,101 - 1,120 results of 27,241 for search '(( 50 ((a decrease) OR (mean decrease)) ) OR ( 50 ((nn decrease) OR (we decrease)) ))', query time: 0.76s Refine Results
  1. 1101
  2. 1102
  3. 1103
  4. 1104
  5. 1105
  6. 1106
  7. 1107
  8. 1108

    Dimerization of [Fe<sup>III</sup>(bpy)<sub>3</sub>]<sup>3+</sup> in Aqueous Solutions: Elucidating a Mechanism Based on Historical Proposals, Electrochemical Data, and Computationa... by Nicolas E. Holubowitch (9254254)

    Published 2022
    “…Despite these favorable characteristics, its oxidized Fe­(III) form undergoes dimerization to form μ-O-[Fe<sup>III</sup>(bpy)<sub>2</sub>(H<sub>2</sub>O)]<sub>2</sub><sup>4+</sup>, leading to a dramatic ∼0.7 V decrease during battery discharge. …”
  9. 1109
  10. 1110
  11. 1111
  12. 1112
  13. 1113
  14. 1114
  15. 1115
  16. 1116

    Circadian Genes, <i>xBmal1</i> and <i>xNocturnin</i>, Modulate the Timing and Differentiation of Somites in <i>Xenopus laevis</i> by Kristen L. Curran (95520)

    Published 2014
    “…We observed opposing effects on somite size. Depletion of xBMAL1 or xNOCTURNIN caused a statistically significant decrease in somite area (quantified using NIH ImageJ; p<0.002), while overexpression of these proteins caused a significant dose dependent increase in somite area (p<0.02; p<0.001, respectively). …”
  17. 1117
  18. 1118

    Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from <i>Gastrocnemius</i> Muscle by Guillaume Caron (816032)

    Published 2015
    “…After toxin injection, we observed a complete paralysis associated to a loss of force to muscle stimulation and a significant muscle atrophy, and a return to baseline when the animals recover. …”
  19. 1119
  20. 1120

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”